Formulation and Evaluation of Canagliflozin-Loaded Nanostructured Lipid Carries

Abstract

Aim of this research work is to develop and evaluate Canagliflozin-loaded Nanostructured Lipid Carriers (NLCs) to improve the drug’s solubility, oral bioavailability, and therapeutic efficacy in type 2 diabetes mellitus.

NLCs was formulated by using suitable solid and liquid lipids with surfactants, followed by characterization through particle size, zeta potential, entrapment efficiency, in vitro release profile, morphological analysis via TEM, and stability evaluation of the optimized formulation. Canagliflozin-loaded NLCs were prepared using a high-speed homogenization method followed by ultrasonication. Various formulations were developed by altering lipid and surfactant composition. The prepared NLCs were evaluated for particle size, zeta potential, drug content, entrapment efficiency, and in vitro drug release. TEM analysis was performed to study morphology. Stability studies were carried out under accelerated conditions in compliance with ICH guidelines.

FTIR study was conducted for identifying functional groups and drug-excipient compatibility study and found that they are compatible with each other. The in-vitro drug release profile confirmed improved release characteristics. The optimized formulation (CF3) exhibited favourable particle size of 305 nm, high drug content of 96.23 %, and high entrapment efficiency of 94.56%. TEM images confirmed smooth and spherical particle morphology, indicating successful NLC formation. Stability studies shown good physical stability under accelerated conditions and there were no significant changes in the physic-chemical properties of formulation. So it was concluded that, the Canagliflozin-loaded NLCs are potential and effective drug delivery system